Business
Past President of the American Burn Association Dr. David Ahrenholz Provides Video Interview on Potential of ESS for Treatment of Severe Burns
Past President of the American Burn Association Dr. David Ahrenholz Provides Video Interview on Potential of ESS for Treatment of Severe Burns.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n\n SAN FRANCISCO and GENEVA, Oct. 14, 2015 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan indications and neurology, provided shareholders with a testimonial video on the potential of Engineered Skin Substitute (ESS) for the treatment of severe burns. A link to clips from the video interview can be found at http://www.amarantus.com/news/videos.\n “The fact the ESS is not on the market is the biggest disappointment of my entire career,” said Dr. David Ahrenholz, retired burn surgeon and past President of the American Burn Association. “I believe ESS will be a game-changing treatment for adult and pediatric severe burns and am committed to helping Amarantus bring this life saving treatment to market for the benefit of patients and their families.” About Engineered Skin Substitute (ESS) Engineered Skin Substitute (ESS) is a tissue-engineered skin prepared from autologous (patient's own) skin cells. It is a combination of cultured epithelium with a collagen-fibroblast implant that produces a skin substitute that contains both epidermal and dermal components. This model has been shown in preclinical studies to generate a permanent functional skin barrier. Most importantly, self-to-self skin grafts for autologous skin tissue are less likely to be rejected by the immune system of the patient, unlike with porcine or cadaver grafts in which immune system rejection is a possibility. ESS has been used in an investigator initiated clinical setting in over 130 human subjects, primarily pediatric patients, for the treatment of severe burns up to 95% total body surface area. About Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings (OTCQX:AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology and orphan diseases. The Company has an exclusive worldwide license to intellectual property rights associated to Engineered Skin Substitute (ESS), an orphan drug designated autologous full thickness skin replacement product in development for the treatment of adult severe burns currently preparing to enter Phase 2 clinical studies. The Company is currently evaluating human clinical data from previously conducted studies in pediatric severe burns and...